{"id":146840,"date":"2025-03-30T16:00:00","date_gmt":"2025-03-30T10:30:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=146840"},"modified":"2025-03-29T11:48:41","modified_gmt":"2025-03-29T06:18:41","slug":"pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/","title":{"rendered":"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3896815014\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>This Pharma stock, which deals in the business of an integrated, R&amp;D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 &amp; FY26 despite uncertainties.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-250108370\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Share Price Movement&nbsp;<\/strong><\/h2><p>In Friday\u2019s trading session, <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/NATCOPHARM\" target=\"_blank\" rel=\"noreferrer noopener\">Natco Pharma<\/a><\/strong>&#8216;s share price was down by 3 percent and closed at Rs. 797.70 per share from the previous close of Rs. 822.40 per share.\u00a0<\/p><p>In the past year, the stock has given around 12.85 percent negative returns, and compared to the Nifty Index, Natco Pharma has underperformed.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Future Plans<\/strong><\/h2><p>In the coming years, Natco Pharma plans to strengthen its core business and expand globally. They aim to achieve Rs. 1,800 to Rs. 2,000 crore PAT for FY25, maintaining similar profitability in FY26 due to anticipation of price erosion in key products like Revlimid.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-1292283909\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>The company expects to capture one-third of the Revlimid market allocation in FY26, contributing significantly to revenues. The Crop Health Sciences division targets Rs. 130 to Rs. 140 crore revenue for FY26, with breakeven expected.&nbsp;<\/p><p>They plan to scale up the Emerging Market and Canada business while targeting 7 to 8 key oncology product launches. Additionally, The launch of Semaglutide injectable in India by March 2026, is subject to regulatory approvals.&nbsp;<\/p><p>Further, Natco is actively pursuing acquisitions in ROW markets and the US front-end, while intending to deploy Rs. 3,000 crore net cash position to fuel its growth. Their R&amp;D spend to remain around 8 to 10 percent of sales.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financials<\/strong><\/h2><p>In its latest filing for the quarter ending December 2024, the company reported a 37.41 percent decline in revenue, reaching Rs. 475 crore compared to Rs. 759 crore in Q3FY24. During the same period, net profit declined by 38.02 percent from Rs. 213 crore in Q3FY24 to Rs. 132 crore in Q3FY25.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Business Segments<\/strong><\/h2><p>The company earned 96.81 percent of its operational revenue from Pharmaceuticals and the remaining 3.18 percent from Agro Chemicals for the December 2024 quarter.<\/p><p>Out of total income, Exporting Formulations contributed 43.89 percent, followed by 28.79 percent from Other Operating &amp; Non- Operating Income, Domestic Formulations contributed 14.75 percent, Active Pharmaceutical Ingredients (API) 10.22 percent, followed by&nbsp;&nbsp;<\/p><div class=\"trade-content-10\" id=\"trade-891998498\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Company Profile&nbsp;<\/strong><\/h2><p>Natco Pharma Limited, founded in 1981 and headquartered in Hyderabad, India, is a leading pharmaceutical company that specializes in oncology, complex generics, and APIs. They operate in over 50 countries and focus on affordable healthcare solutions. It also diversifies into agrochemicals and renewable energy.<\/p><p>They have around 28 products in the pipeline focused on Cancer, Hypertension, Weight Loss, Bladder Cancer, Breast Cancer, and others as of December 31st, 2024 in the USA.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by &#8211; Santhosh S<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses ca<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1797263965\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>This Pharma stock, which deals in the business of an integrated, R&amp;D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 &amp; FY26 despite uncertainties. Share Price Movement&nbsp; In Friday\u2019s trading session, Natco Pharma&#8216;s share price was down by [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":111747,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[18716,24978,17712,14315,948,936,2597],"class_list":["post-146840","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-natco-pharma","tag-natco-pharma-latest-news-2","tag-natco-pharma-latest-news","tag-natco-pharma-share-price","tag-stock-market","tag-stock-market-news","tag-stocks-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"This Pharma stock, which deals in the business of an integrated, R&amp;D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 &amp; FY26 despite uncertainties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist\" \/>\n<meta property=\"og:description\" content=\"This Pharma stock, which deals in the business of an integrated, R&amp;D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 &amp; FY26 despite uncertainties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-30T10:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/\",\"name\":\"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"datePublished\":\"2025-03-30T10:30:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"This Pharma stock, which deals in the business of an integrated, R&D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 & FY26 despite uncertainties.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist - Trade Brains Features","description":"This Pharma stock, which deals in the business of an integrated, R&D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 & FY26 despite uncertainties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist","og_description":"This Pharma stock, which deals in the business of an integrated, R&D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 & FY26 despite uncertainties.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-03-30T10:30:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/","name":"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","datePublished":"2025-03-30T10:30:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"This Pharma stock, which deals in the business of an integrated, R&D-focused pharmaceutical company that is engaged in manufacturing, developing, and marketing complex products for niche therapeutic areas, plans to reach Rs. 2,000 Cr PAT in FY25 & FY26 despite uncertainties.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/10\/pharma03.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-with-2000-cr-net-profit-guidance-for-fy26-to-add-to-your-watchlist\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock with \u20b92000 Cr net profit guidance for FY26 to add to your watchlist"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/146840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=146840"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/146840\/revisions"}],"predecessor-version":[{"id":146841,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/146840\/revisions\/146841"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/111747"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=146840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=146840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=146840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}